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Abstract: A 61-year-old Japanese woman underwent a partial
mastectomy for cancer of the right breast (pT1cN0M0, stage I).
Eight months later, chest computed tomography revealed two small
nodules in the left lower lobe (Segmentum basale laterale and
Segmentum basale posterius; S9 and S10). She thereafter underwent
partial pulmonary resections for both diagnostic and treatment
purposes. The nodule of S10 was pathologically diagnosed to be
primary lung cancer. The nodule of S9 was pathologically diagnosed
to be poorly differentiated adenocarcinoma. The same pattern of the
distribution of the p53 mutation was observed in the DNA samples
of the S9 nodule and the treated breast cancer. We therefore finally
diagnosed the S9 nodule to be metastatic pulmonary carcinoma. A
mutation analysis of the p53 gene is thus considered to be a good
modality for differentiating metastases from primary carcinomas of
the lung.
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The lung is one of the most common organs to which manycarcinomas, including lung carcinomas, metastasize.1 The
incidence of multiple lung cancers in clinical reports ranges
from 1 to 7%.2 Therefore, the differential diagnosis of pul-
monary nodules is important. When a clinician identifies
multiple synchronous lung tumors, differentiating multicen-
tric lung cancers, a single lung cancer with intrapulmonary
metastases, or pulmonary metastases from primary cancer in
different organs can often be difficult. When we need to
differentiate between primary and metastasis for the diagno-
sis of multiple lung lesions, it is therefore useful to analyze
the patterns of some genetic alterations.
CASE REPORT
A 61-year-old Japanese woman underwent a total thy-
roidectomy for a left thyroid cancer (pT1N0M0, stage I) in
2004. The lesion showed papillary growth histologically, and
was immunohistochemically positive for thyroglobulin. The
next year, the patient underwent a partial mastectomy for a
right breast cancer (pT1cN0M0, stage I). Microscopically,
the tumor consisted of a well demarcated round nodule with
focal invasion to adipose tissue in the breast (Figure 1).
Neither estrogen (ER) nor progesterone receptors were im-
munohistochemically detected in the tumor cells. After 8
months, a follow-up chest computed tomographic scan re-
vealed two small nodules in the left lower lobe (Segmentum
basale laterale and Segmentum basale posterius; S9 and S10,
measuring 10 mm and 8 mm, respectively). The computed
tomography findings of the nodule in S9 revealed a solid
density with a regular margin (Figure 2A). The findings of
S10 revealed a solid density with a focal irregular margin
(Figure 2B). We clinically diagnosed those lesions as meta-
static lung cancer from the treated malignant lesions. The
patient underwent a partial pulmonary resections by using a
video assisted thoracoscopic approach for the malignant le-
sions on December 4, 2006. Microscopically, the tumor cells
were cuboidal to columnar shaped cells growing along the
alveolar walls in the S10 (Figure 3A). The immunohisto-
chemical staining was positive for thyroid transcription factor
1 and P53. It was negative for thyroglobulin and ER. The
nodule was pathologically diagnosed as a primary lung can-
cer (type B disease based on the Noguchi’s classification3).
But another tumor in the S9 was a poorly differentiated
subtype of adenocarcinoma with intracytoplasmic mucin
droplets (Figure 3B), and immunostaining was negative for
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ER, progesterone receptor, thyroid transcription factor 1, and
thyroglobulin. It was positive for P53. In particular, it was not
possible to judge the S9 nodule morphologically by micro-
scopic examination to see whether it was a primary lung
cancer or a metastatic lesion from the treated breast cancer.
Direct sequencing mutation analyses of p53 and the K-ras
gene were performed for the differential diagnosis by the
following methods. After we obtained consent from the
patient, DNAs were purified from the tumor tissue. About six
10 m sections were cut from the formalin-fixed block. The
slices were deparaffinized with xylene, and genomic DNA
were extracted from the tumor and nontumor samples using
the DNeasy kit (Qiagen, Valencia, CA). Exons 5, 6, 7, and 8
of the p53 gene were amplified by polymerase chain reaction
(PCR) using specific oligonucleotide primers. The primers
used for the amplification of exons were designed based on
the published sequences.4 The DNA was subjected to 40
cycles of PCR (95, 58, and 72°C for 0.5, 0.5, and 0.5 minutes,
respectively) in PerfectShot Ex Taq (Takara Bio Inc. Japan).
The PCR products were sequenced directly using a BigDye
Terminator Cycle Sequencing Kit and an Applied Biosystems
sequencer model 310 (Applied Biosystems, Foster City, CA).
A different pattern of the distribution of the p53 mutation in
the two nodules was observed (Figure 4A, B), and the same
pattern of the distribution of the p53 mutation was observed
in the DNA samples of the S9 nodule and the treated breast
cancer. The mutation was detected in exon 6 (Figure 4B, C).
These tumors had a C-to-T transition at codon 213. However,
the K-ras mutation was not detected in any of the tumor
samples. Therefore, we diagnosed the S9 nodule to be met-
astatic pulmonary carcinoma from the treated breast cancer
based on the results of the p53 mutation analysis.
DISCUSSION
Cancers of similar histologic types in different organs
often share similar histologic, and even similar immunohis-
tochemical features. Therefore, it would be expected that the
patterns of some genetic alterations may serve as a discrim-
ination marker of multiple lung lesions. The p53 gene is
localized on chromosome 17 (short arm, 17p13), a region that
is frequently deleted in human cancer. It is one of the tumor
suppressor genes, and codes for a 53-kDa nuclear protein.
Mutations of the p53 gene at a highly conserved sequence and
alteration in the expression of the P53 protein are frequently
present in human malignancies. In addition, a p53 mutation is
one common genetic change in nonsmall cell lung cancer. Chiba
et al.5 reported that mutations changing the p53 coding sequence
were found in 23/51 (45%) nonsmall cell lung cancer specimens,
but not in the corresponding normal lung, and they were distrib-
FIGURE 1. Microscopic findings of the right breast tumor
reveal a ductal cancer cell type, and growth in well-defined
nests (H&E stain, 200).
FIGURE 2. Chest CT image of the left lower
lobe (S9) shows a solid density with a regular
margin, and the size is a 10  10 mm (A). CT
image of the left lower lobe (S10) shows a solid
density with a focal irregular margin on the lung
window, and the size is a 8  8 mm (B).
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uted between codons 132 and 283. In breast cancer, the p53
mutation rate is about 20%. In addition, the p53 mutation has
been demonstrated to usually precede metastasis, while it is also
conserved in metastases. Therefore, the analysis of the p53
mutation pattern can be used as a clonal marker for the differ-
ential diagnosis of multiple cancers.6
In 1992, Oda et al.6 reported the p53mutation pattern to
be useful for distinguishing a primary tumor from metastasis
and/or a second primary tumor from a recurrence in hepato-
cellular carcinomas. With other organs, the mutation pattern
has been used to establish a differential diagnosis in ovarian
cancers,7 urothelial carcinomas,8 and head and neck cancers.9
With respect to lung cancer, a comparison of p53
mutations between primary lung cancer and metastatic lung
tumors, primary lung tumors and metastases to other or-
gans,10 or second primary lung cancer and metastasis1 has
FIGURE 3. A, Microscopic findings of the resected tumor in
the S10 reveal cuboidal to columnar shaped cells growing
along the alveolar walls (H&E stain, A 200). B, Microscopic
findings of resected tumor in the S9 reveal a poorly differen-
tiated subtype of adenocarcinoma with intracytoplasmic mu-
cin droplets (H&E stain, B 400).
FIGURE 4. A sequence analysis of exon 6 from the tumor
tissues. Codon 213 (the arrow) in the lung tumor of S10 is
the normal base sequence (A). The arrow indicates a point
mutation (codon 213; CGA3TGA) in the lung tumor of S9
(B). The arrow indicates the point mutation (codon 213;
CGA3TGA) in the breast cancer (C).
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been reported. These authors used PCR-single-strand confor-
mation polymorphism as the method for performing a gene
mutation analysis. The DNAs with mutations and those
without mutations were able to be separated using TaqI
(Takara Bio Inc., Japan) of the restriction enzyme. The band
of mutated DNAs in polyacrylamide gels were cut out and
then were further analyzed for their nucleotide sequences by
the direct sequencing method (Fig. 4A–C).
In conclusion, when pulmonary tumors are observed in
patients with a history of cancer, the differentiation between
metastasis and primary lung cancer thus plays a crucial role in
selecting the appropriate therapy for such patients. Assuming
that we need to differentiate between primary and metas-
tasis for the diagnoses of multiple lung lesions, a mutation
analysis of the p53 gene is thus considered to be a good
modality for differentiating metastases from primary car-
cinomas of the lung.
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